Related Experiment Video
Updated: Apr 21, 2026
03:37
Self-Administration of Drugs in Mouse Models of Feeding and Obesity
Published on: June 8, 2021
5.5K
A case of priapism with risperidone.
Almari Ginory1, Mathew Nguyen1
1Department of Psychiatry, University of Florida, Gainesville, FL 32610, USA.
Case Reports in Psychiatry
|November 8, 2014
Summary
Priapism, a prolonged erection, can be a side effect of antipsychotic medications like risperidone. Patients with a history of priapism should be monitored closely when prescribed new psychotropic drugs.
Area of Science:
- Urology
- Pharmacology
- Psychiatry
Background:
- Priapism is a urologic emergency characterized by prolonged penile erection.
- Psychotropic medications, particularly antipsychotics, are known causes of priapism.
- Alpha-1 antagonism is a proposed mechanism for antipsychotic-induced priapism.
Purpose of the Study:
- To report a case of new-onset priapism associated with risperidone in a patient with a history of schizophrenia and trazodone-induced priapism.
- To highlight the importance of considering prior medication-induced priapism when prescribing psychotropic agents.
Main Methods:
- Case report of a 50-year-old male with schizophrenia.
- Clinical presentation of new-onset priapism.
- Treatment involved discontinuation of risperidone, corpus cavernosum drainage, and intracavernosal phenylephrine injections.
Main Results:
- The patient experienced priapism while on risperidone.
- Successful treatment was achieved with conservative measures and medication cessation.
Conclusions:
- Risperidone can induce priapism, potentially through alpha-1 antagonism.
- Patients with a history of medication-induced priapism have an increased risk.
- Patient education and careful medication history are crucial in managing psychotropic drug prescriptions.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:15REM Sleep Behavior Disorder
2.8K
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
RBD is significantly associated with...
2.8K
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
797
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
797
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
628
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
628
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
367
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
367
01:23Antidepressant Drugs: MAOIs and Other Agents
1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K